Vaccine hesitancy is considered a major barrier to achieving herd immunity against COVID-19. While multiple alternative and synergistic approaches including heterologous vaccination, booster doses, and antiviral drugs have been developed, equitable vaccine uptake remains the foremost strategy to manage pandemic. Although none of the currently approved vaccines are live-attenuated, several reports of disease flares, waning protection, and acute-onset syndromes have emerged as short-term adverse events after vaccination. Hence, scientific literature falls short when discussing potential long-term effects in vulnerable cohorts. The COVAD-2 survey follows on from the baseline COVAD-1 survey with the aim to collect patient-reported data on the long-term safety and tolerability of COVID-19 vaccines in immune modulation. The e-survey has been extensively pilot-tested and validated with translations into multiple languages. Anticipated results will help improve vaccination efforts and reduce the imminent risks of COVID-19 infection, especially in understudied vulnerable groups.
COVAD survey 2 long-term outcomes: unmet need and protocol / Fazal, Z. Z.; Sen, P.; Joshi, M.; Ravichandran, N.; Lilleker, J. B.; Agarwal, V.; Kardes, S.; Kim, M.; Day, J.; Makol, A.; Milchert, M.; Gheita, T.; Salim, B.; Velikova, T.; Gracia-Ramos, A. E.; Parodis, I.; Nikiphorou, E.; Tan, A. L.; Chatterjee, T.; Cavagna, L.; Saavedra, M. A.; Shinjo, S. K.; Ziade, N.; Selva-O'Callaghan, A.; Nune, A.; Knitza, J.; Kuwana, M.; Gutierrez, C. -E. T.; Caballero-Uribe, C. V.; Dey, D.; Distler, O.; Chinoy, H.; Agarwal, V.; Aggarwal, R.; Gupta, L.; Barman, B.; Singh, Y. P.; Ranjan, R.; Jain, A.; Pandya, S. C.; Pilania, R. K.; Sharma, A.; M, M. M.; Gupta, V.; Kavadichanda, C. G.; Patro, P. S.; Ajmani, S.; Phatak, S.; Goswami, R. P.; Chowdhury, A. C.; Mathew, A. J.; Shenoy, P.; Asranna, A.; Bommakanti, K. T.; Shukla, A.; Pandey, A. K. R.; Gaur, P. S.; Mamadapur, M.; Ghodke, A.; Chandwar, K.; Jagtap, K.; Cansu, D. U.; Yildirim, R.; Patel, A.; Pauling, J. D.; Wincup, C.; Giannini, M.; Maurier, F.; Campagne, J.; Meyer, A.; Del Papa, N.; Sambataro, G.; Fabiola, A.; Govoni, M.; Parisi, S.; Bocci, E. B.; Sebastiani, G. D.; Fusaro, E.; Sebastiani, M.; Quartuccio, L.; Franceschini, F.; Sainaghi, P. P.; Orsolini, G.; De Angelis, R.; Danielli, M. G.; Venerito, V.; Grignaschi, S.; Giollo, A.; Traboco, L. S.; Shaharir, S. S.; Wibowo, S. A. K.; Tehozol, E. A. Z.; Serrano, J. R.; La Torre, I. G. -D.; Colunga-Pedraza, I. J.; Colunga-Pedraza, I. J.; Merayo-Chalico, J.; Loarce-Martos, J.; Prieto-Gonzalez, S.; Gil-Vila, A.; Aranega, R.; Hoff, L. S.; Nakashima, R.; Sato, S.; Kimura, N.; Kaneko, Y.; Tomaras, S.; Proft, F. N.; Holzer, M. -T.; Gromova, M. A.; Aharonov, O.; Nagy-Vincze, M.; Griger, Z.; Hmamouchi, I.; El bouchti, P. I.; Baba, Z.; Ima-Edomwonyi, U.; Dedeke, I.; Airenakho, E.; Madu, N. H.; Yerima, A.; Olaosebikan, H.; Chibuzo, O. C.; A, B.; Koussougbo, O. D.; Palalane, E.; Langguth, D.; Limaye, V.; Needham, M.; Srivastav, N.; Hudson, M.; Landon-Cardinal, O.; Zuleta, W. G. R.; Arbelaez, A.; Cajas, J.; Silva, J. A. P.; Fonseca, J. E.; Zimba, O.; Bohdana, D.; So, H.; Ugarte-Gil, M. F.; Chinchay, L.; Bernaola, J. P.; Pimentel, V.; Tanveer Hasan, A. T. M.; Saha, S.; Vaidya, B.; Fathi, H. M.; Mohammed, R. H. A.; Chen, Y. -M.; Harifi, G.; El Kibbi, L.; Halabi, H. M.; Akawatcharangura, P.; Katchamart, W.; Fuentes-Silva, Y.; Cabriza, K.; Losanto, J.; Colaman, N.; Cachafeiro-Vilar, A.; Bautista, G. G.; Ho, E. J. G.; Gonzalez, R. A.; Nunez, L. S.; M, C. V.; Baez, J. T.; Alonzo, H.; Pastelin, C. B. S.; Salinas, R. G.; Obiols, A. Q.; Chavez, N.; Ordonez, A. B.; Argueta, S.; Quijivix, D.; Llerena, G. A. R.; Sierra-Zorita, R.; Arrieta, D.; Hidalgo, E. R.; Saenz, R.; M, I. E.; Morales, R.; Calapaqui, W.; Quezada, I.; Arredondo, G.. - In: RHEUMATOLOGY INTERNATIONAL. - ISSN 1437-160X. - 42:12(2022), pp. 2151-2158. [10.1007/s00296-022-05157-6]
COVAD survey 2 long-term outcomes: unmet need and protocol
Sebastiani M.;
2022
Abstract
Vaccine hesitancy is considered a major barrier to achieving herd immunity against COVID-19. While multiple alternative and synergistic approaches including heterologous vaccination, booster doses, and antiviral drugs have been developed, equitable vaccine uptake remains the foremost strategy to manage pandemic. Although none of the currently approved vaccines are live-attenuated, several reports of disease flares, waning protection, and acute-onset syndromes have emerged as short-term adverse events after vaccination. Hence, scientific literature falls short when discussing potential long-term effects in vulnerable cohorts. The COVAD-2 survey follows on from the baseline COVAD-1 survey with the aim to collect patient-reported data on the long-term safety and tolerability of COVID-19 vaccines in immune modulation. The e-survey has been extensively pilot-tested and validated with translations into multiple languages. Anticipated results will help improve vaccination efforts and reduce the imminent risks of COVID-19 infection, especially in understudied vulnerable groups.
| File | Dimensione | Formato | |
|---|---|---|---|
|
s00296-022-05157-6.pdf
Open access
Tipologia:
Versione pubblicata dall'editore
Dimensione
634.01 kB
Formato
Adobe PDF
|
634.01 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
